Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly

Devasmita Choudhury, Meryem Tuncel, Moshe Levi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The growing population of elderly with chronic kidney disease (CKD) is at greater risk for cardiovascular disease given an independent risk of CKD, as well as from added dyslipidemia of aging and renal dysfunction. Changes in lipid metabolism with more isodense and high-dense, triglyceride-rich particles, low high-density lipoprotein cholesterol, and increased triglyceride levels occur with CKD and aging, which are noted to have significant atherogenic potential. In addition, lipid abnormalities may lead to the progression of CKD. Cardiovascular mortality in the end-stage renal disease population is more than 10 times higher than the general population. Treatment of dyslipidemia in the general population suggests important benefits both in reducing cardiovascular risk and in the prevention of cardiovascular disease. Secondary analyses of elderly subgroups of various large prospective studies with statins suggest treatment benefit with statin use in the elderly. Similarly limited data from secondary analyses of CKD subgroups of larger prospective trials using statins also suggest a possible benefit in cardiovascular outcomes and the progression of kidney disease. However, randomized trials have yet to confirm similar benefits and targets of treatment for dyslipidemia in the elderly with CKD and end-stage renal disease. Treatment in the elderly with CKD should be individualized and outweigh risks of side effects and drug-drug interactions. There is a need for further specific investigation of dyslipidemia of CKD in the aging population in relation to renal disease progression and cardiovascular outcome.

Original languageEnglish (US)
Pages (from-to)610-620
Number of pages11
JournalSeminars in Nephrology
Volume29
Issue number6
DOIs
StatePublished - Nov 2009

Fingerprint

Lipid Metabolism Disorders
Chronic Renal Insufficiency
Dyslipidemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Population
Chronic Kidney Failure
Triglycerides
Cardiovascular Diseases
Kidney
Kidney Diseases
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Drug Interactions
Lipid Metabolism
LDL Cholesterol
HDL Cholesterol
Disease Progression
Prospective Studies
Lipids

Keywords

  • chronic kidney disease
  • dyslipidemia
  • elderly
  • end-stage renal disease
  • Lipid disorder

ASJC Scopus subject areas

  • Nephrology

Cite this

Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly. / Choudhury, Devasmita; Tuncel, Meryem; Levi, Moshe.

In: Seminars in Nephrology, Vol. 29, No. 6, 11.2009, p. 610-620.

Research output: Contribution to journalArticle

Choudhury, Devasmita ; Tuncel, Meryem ; Levi, Moshe. / Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly. In: Seminars in Nephrology. 2009 ; Vol. 29, No. 6. pp. 610-620.
@article{5b8945604bde4822b97ad0cf4b7f6635,
title = "Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly",
abstract = "The growing population of elderly with chronic kidney disease (CKD) is at greater risk for cardiovascular disease given an independent risk of CKD, as well as from added dyslipidemia of aging and renal dysfunction. Changes in lipid metabolism with more isodense and high-dense, triglyceride-rich particles, low high-density lipoprotein cholesterol, and increased triglyceride levels occur with CKD and aging, which are noted to have significant atherogenic potential. In addition, lipid abnormalities may lead to the progression of CKD. Cardiovascular mortality in the end-stage renal disease population is more than 10 times higher than the general population. Treatment of dyslipidemia in the general population suggests important benefits both in reducing cardiovascular risk and in the prevention of cardiovascular disease. Secondary analyses of elderly subgroups of various large prospective studies with statins suggest treatment benefit with statin use in the elderly. Similarly limited data from secondary analyses of CKD subgroups of larger prospective trials using statins also suggest a possible benefit in cardiovascular outcomes and the progression of kidney disease. However, randomized trials have yet to confirm similar benefits and targets of treatment for dyslipidemia in the elderly with CKD and end-stage renal disease. Treatment in the elderly with CKD should be individualized and outweigh risks of side effects and drug-drug interactions. There is a need for further specific investigation of dyslipidemia of CKD in the aging population in relation to renal disease progression and cardiovascular outcome.",
keywords = "chronic kidney disease, dyslipidemia, elderly, end-stage renal disease, Lipid disorder",
author = "Devasmita Choudhury and Meryem Tuncel and Moshe Levi",
year = "2009",
month = "11",
doi = "10.1016/j.semnephrol.2009.07.006",
language = "English (US)",
volume = "29",
pages = "610--620",
journal = "Seminars in Nephrology",
issn = "0270-9295",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly

AU - Choudhury, Devasmita

AU - Tuncel, Meryem

AU - Levi, Moshe

PY - 2009/11

Y1 - 2009/11

N2 - The growing population of elderly with chronic kidney disease (CKD) is at greater risk for cardiovascular disease given an independent risk of CKD, as well as from added dyslipidemia of aging and renal dysfunction. Changes in lipid metabolism with more isodense and high-dense, triglyceride-rich particles, low high-density lipoprotein cholesterol, and increased triglyceride levels occur with CKD and aging, which are noted to have significant atherogenic potential. In addition, lipid abnormalities may lead to the progression of CKD. Cardiovascular mortality in the end-stage renal disease population is more than 10 times higher than the general population. Treatment of dyslipidemia in the general population suggests important benefits both in reducing cardiovascular risk and in the prevention of cardiovascular disease. Secondary analyses of elderly subgroups of various large prospective studies with statins suggest treatment benefit with statin use in the elderly. Similarly limited data from secondary analyses of CKD subgroups of larger prospective trials using statins also suggest a possible benefit in cardiovascular outcomes and the progression of kidney disease. However, randomized trials have yet to confirm similar benefits and targets of treatment for dyslipidemia in the elderly with CKD and end-stage renal disease. Treatment in the elderly with CKD should be individualized and outweigh risks of side effects and drug-drug interactions. There is a need for further specific investigation of dyslipidemia of CKD in the aging population in relation to renal disease progression and cardiovascular outcome.

AB - The growing population of elderly with chronic kidney disease (CKD) is at greater risk for cardiovascular disease given an independent risk of CKD, as well as from added dyslipidemia of aging and renal dysfunction. Changes in lipid metabolism with more isodense and high-dense, triglyceride-rich particles, low high-density lipoprotein cholesterol, and increased triglyceride levels occur with CKD and aging, which are noted to have significant atherogenic potential. In addition, lipid abnormalities may lead to the progression of CKD. Cardiovascular mortality in the end-stage renal disease population is more than 10 times higher than the general population. Treatment of dyslipidemia in the general population suggests important benefits both in reducing cardiovascular risk and in the prevention of cardiovascular disease. Secondary analyses of elderly subgroups of various large prospective studies with statins suggest treatment benefit with statin use in the elderly. Similarly limited data from secondary analyses of CKD subgroups of larger prospective trials using statins also suggest a possible benefit in cardiovascular outcomes and the progression of kidney disease. However, randomized trials have yet to confirm similar benefits and targets of treatment for dyslipidemia in the elderly with CKD and end-stage renal disease. Treatment in the elderly with CKD should be individualized and outweigh risks of side effects and drug-drug interactions. There is a need for further specific investigation of dyslipidemia of CKD in the aging population in relation to renal disease progression and cardiovascular outcome.

KW - chronic kidney disease

KW - dyslipidemia

KW - elderly

KW - end-stage renal disease

KW - Lipid disorder

UR - http://www.scopus.com/inward/record.url?scp=71549119170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549119170&partnerID=8YFLogxK

U2 - 10.1016/j.semnephrol.2009.07.006

DO - 10.1016/j.semnephrol.2009.07.006

M3 - Article

VL - 29

SP - 610

EP - 620

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

IS - 6

ER -